Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Innovent reports significant weight loss, multiple metabolic benefits, and positive safety record with a higher 9mg dose of Mazdutide (IBI362), after a 48-week Phase 2 trial for obesity
3 November 2023
Innovent reports substantial weight reduction, several metabolic advantages, and a good safety record with a higher dose of 9 mg Mazdutide (IBI362) following a 48-week trial in phase 2 study for obesity.
Drug Insights
4 min read
Decoding Etelcalcetide: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
3 November 2023
This article summarized the latest R&D progress of Etelcalcetide, the mechanism of action for Etelcalcetide, and the drug target R&D trends for Etelcalcetide.
Latest Hotspot
3 min read
Germany's Merck KGaA enhances its oncology portfolio by partnering strategically with Hengrui for advanced PARP1 inhibitor and antibody-drug conjugate
3 November 2023
Merck KGaA, Darmstadt, has formed a strategic partnership with Jiangsu Hengrui Pharmaceuticals Co. Ltd. It holds a global exclusive license to develop, manufacture, and distribute Hengrui’s advanced PARP1 trapping inhibitor HRS-1167.
Bio Sequence
2 min read
Biological Glossary | What is Enhancer?
3 November 2023
Enhancers are one type of DNA sequence that has important functions in biology.
Latest Hotspot
4 min read
Coherus and Junshi Biosciences reveal FDA validation for LOQTORZI™ (toripalimab-tpzi) in all treatment phases for repeated or spreading Nasopharyngeal Cancer (NPC)
3 November 2023
Coherus BioSciences, Inc. along with Shanghai Junshi Biosciences Co., Ltd. revealed that the FDA has given its approval for LOQTORZI™ (toripalimab-tpzi) to be used with cisplatin and gemcitabine.
Drug Insights
4 min read
Deep Scientific Insights on Eteplirsen's R&D Progress, Mechanism of Action, and Drug Target
3 November 2023
This article summarized the latest R&D progress of Eteplirsen, the mechanism of action for Eteplirsen, and the drug target R&D trends for Eteplirsen.
Latest Hotspot
3 min read
Kymera Therapeutics starts Phase 2 trial of KT-474 (SAR444656), a new IRAK4 degrader, on its first Hidradenitis Suppurativa patient
3 November 2023
Kymera Therapeutics discloses initiation of Phase 2 trial with KT-474 (SAR444656), a novel IRAK4 degrader, being administered to its first Hidradenitis Suppurativa patient.
Bio Sequence
3 min read
The Evolution of the Competitive Landscape Behind Regeneron's Pleasing Sales of High-dose Treatment for Macular Degeneration, Eylea
3 November 2023
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Aflibercept patent are Novartis with 80 applications, Regeneron with 60 applications, and Sanofi with 50 applications.
Latest Hotspot
3 min read
Otsuka Pharmaceutical unveils Phase 3 studies of Centanafadine for treating Attention Deficit Hyperactivity Disorder in children and teenagers
2 November 2023
Otsuka Pharmaceutical, including its U.S. division, reported promising results from two Phase 3 trials evaluating centanafadine's efficacy and safety in managing ADHD in children and teens.
Drug Insights
5 min read
An In-depth Analysis of Ezetimibe/Simvastatin's R&D Progress and Mechanism of Action on Drug Target
2 November 2023
This article summarized the latest R&D progress of Ezetimibe/Simvastatin, the mechanism of action for Ezetimibe/Simvastatin, and the drug target R&D trends for Ezetimibe/Simvastatin.
Latest Hotspot
3 min read
ImmunoGen Announces EMA Approval of Mirvetuximab Soravtansine's Application for Treating Platinum-Resistant Ovarian Cancer
2 November 2023
ImmunoGen Discloses European Medicines Agency Approval of Mirvetuximab Soravtansine's Marketing Authorization Application for Dealing with Platinum-Resistant Ovarian Cancer.
Drug Insights
4 min read
Fam-trastuzumab deruxtecan-NXKI: Detailed Review of its Transformative R&D Success
2 November 2023
This article summarized the latest R&D progress of Fam-trastuzumab deruxtecan-NXKI, the mechanism of action for Fam-trastuzumab deruxtecan-NXKI, and the drug target R&D trends for Fam-trastuzumab deruxtecan-NXKI.